Corcept Therapeutics Incorporat
Corcept Therapeutics develops treatments for severe disorders. They offer Korlym tablets for endogenous Cushings syndrome. Relacorilant is in Phase III trials for Cushings syndrome, adrenal cancer, cortisol excess, prostate cancer, and platinum-resistant ovarian tumors. Dazucorilant is in Phase II trial for amyotrophic lateral sclerosis. Miricorilant is in Phase IIb trial for nonalcoholic steatohepatitis. They also develop treatments for antipsychotic-induced weight gain.
Overview
Strengths
- Earnings are projected to grow at a solid rate (11.3% per year).
- The company has low debt. Net Debt to EBITDA Ratio is -2.45 and it is lower than the sector mean.
- The company has high returns. ROIC (21.71%) is higher than the sector mean (6.02%).
Weaknesses
- With a depreciation Potential of -89.88%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (123.59) is significantly higher than the sector mean (91.15).
- EV/EBITDA (261.36) is significantly higher than the sector mean (85.60).
- EV/EBIT (272.39) is significantly higher than the sector mean.
- EBITDA Margin (6.13%) appears relatively low.
Key Financial Data